Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
The indications of immune checkpoint inhibitors (ICIs) are set to rise further with the approval of newer agent like atezolimumab for use in patients with advanced stage urothelial carcinoma. More frequent use of ICIs has improved our understanding of their unique side effects, which are known as im...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2017-02-01
|
| coleção: | Frontiers in Pharmacology |
| Assuntos: | |
| Acesso em linha: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00049/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|